Acetylsalicylic acid and atorvastatin in the treatment of castration-resistant prostate cancer


Coordinating investigator

PD Dr. med.
Kantonsspital St. Gallen
+41 71 494 29 22

In recent years, appropriate treatment methods have lengthened the survival times for men with castration-resistant prostate cancer (CRPC): average survival for men with metastasis is 30 months while for those without metastasis it is five years. To bring about further improvements, however, it is important to evaluate other therapy options.

The PEACE-4 study seeks to establish whether the addition of the antithrombotic acetylsalicylic acid and/or the statin atorvastatin to standard CRPC therapy can result in increased survival times.

There are good reasons why these two active substances were chosen. A number of studies have shown that mortality is lower in prostate cancer patients taking acetylsalicylic acid and/or atorvastatin than in those not receiving such medication.

Approximately 1200 patients with CRPC are taking part in the PEACE-4 study.

Provided treatment with the trial drugs is well tolerated, it will be continued until such time as the patient wants it to cease.

All trials